A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

LLY's explosive GLP-1 growth, deep obesity pipeline and strong estimate momentum give it the edge over MRK despite a richer valuation.

Eli Lilly just announced phase 3 clinical trial results for its new medication, retatrutide, and it could become the most ...

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

A federal judicial panel said Monday it would centralize a growing number of lawsuits against Novo Nordisk and Eli Lilly ...

Meanwhile, people with overweight or obesity lost up to 11.3% more weight than placebo by week 36 with a novel GLP-1 agonist ...

There is no exact known number of GLP-1 patients who say their say their sense of taste has changed since starting the ...

Treatment with Kisunla was associated with sustained clinical benefits, specifically less symptom worsening and significant amyloid clearance up to 3 years, in early symptomatic Alzheimer’s disease, ...

Siemens Healthineers has tapped the Alzheimer’s disease blood test developer ALZpath for an in vitro diagnostic to ...

Vivek Ramaswamy has found time out of his campaign for governor of Ohio to launch a new biotech.  | Vivek Ramaswamy has found ...

San Diego–based Ventyx Biosciences has what pharma wants, according to William Blair: two NLRP3 inhibitors for inflammatory ...